Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × ALK+ Advanced NSCLC × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1150 Lung Neoplasms 600 Small Cell Lung Carcinoma 168 Neoplasms 134 Neoplasm Metastasis 107 Breast Neoplasms 94 Adenocarcinoma of Lung 74 Colorectal Neoplasms 73 Melanoma 72 Ovarian Neoplasms 67 Pancreatic Neoplasms 63 Head and Neck Neoplasms 53 Carcinoma, Renal Cell 53 Mesothelioma 51 Prostatic Neoplasms 47 Mesothelioma, Malignant 46 Carcinoma 41 Urinary Bladder Neoplasms 40 Brain Neoplasms 36 Stomach Neoplasms 35 Triple Negative Breast Neoplasms 31 Recurrence 31 Esophageal Neoplasms 31 Colonic Neoplasms 30 Adenocarcinoma 29 Squamous Cell Carcinoma of Head and Neck 28 Adenocarcinoma, Bronchiolo-Alveolar 27 Sarcoma 24 Parkinson Disease 4, Autosomal Dominant Lewy Body 24 Kidney Neoplasms 24

Interventions

brigatinib 1 alectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03596866 2025-09-12

ALTA-3

Takeda

Phase 3 Completed

248 enrolled 20 charts

ALK+ Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡